Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Discovery Platform
Recipient : Blacksmith Medicines
Deal Size : Undisclosed
Deal Type : Merger
Details : The Blacksmith metalloenzyme platform, a focused library of metal-binding pharmacophores with proprietary computational modeling, approaches to rapidly and rationally design small molecule inhibitors that interact with key metal ions in the enzyme's acti...
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
January 02, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Discovery Platform
Recipient : Blacksmith Medicines
Deal Size : Undisclosed
Deal Type : Merger
Lead Product(s) : Undisclosed
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Preclinical
Sponsor : F. Hoffmann-La Roche
Deal Size : $190.5 million
Deal Type : Collaboration
Evotec partner Forge enters into collaboration with Roche to develop novel antibiotic
Details : Under this agreement, Roche has an exclusive option to license one of Forge’s antibiotic programmes. Forge will retain control of the programme prior to Roche exercising its option.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
March 25, 2020
Lead Product(s) : Undisclosed
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Preclinical
Sponsor : F. Hoffmann-La Roche
Deal Size : $190.5 million
Deal Type : Collaboration